ARK-102

N/A

Report date: 2026/04/15 20:02:38

Base Information

Drug NameARK-102

Drug Alias NameARK-102ARK102

ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Multispecific monoclonal antibody > Trispecific monoclonal antibodyBiologics > T cell engagers

Mechanisms of ActionAnti-Trop-2Anti-HER2Anti-CD3

TargetsTumor-associated calcium signal transducer 2Receptor protein-tyrosine kinase erbB-2T cell surface glycoprotein CD3

Therapy Area/IndicationsSolid tumours

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritorySouth Korea

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesARKgen BioScions Inc

China Registration ClassN/A

Develop Information

Active CompaniesARKgen BioScions Inc

Inactive CompaniesN/A

Active IndicationsSolid tumours

Inactive IndicationsN/A

Other Information

ATC CodeN/A